Report Keywords –Antibody Drug, Conjugates, Roots Analysis, Biotech, Analysis
Antibody drug conjugates (ADCs) represent a transformativeapproach to modern cancer treatment; over the years, this upcoming class oftargeted therapeutic agents has generated significant enthusiasm within themedical science community
Roots Analysis is pleased to announce the publication of its recentstudy, titled, “ Antibody Drug Conjugates Market(5th Edition), 2019-2030.”
The report features an extensive study of the currentmarket landscape, offering an informed opinion on the likely adoption of thesetherapeutics over the next decade. It features an in-depth analysis, highlightingthe capabilities of various stakeholders engaged in this domain. In addition toother elements, the study includes:
§ Adetailedassessment of the current market landscape of ADCs.
§ Elaborate profiles of the clinical stage companies(shortlisted based on phase of development of the lead drug) and theirrespective product portfolios.
§ An analysis of the most commonly targeted therapeuticindications and details of ADC candidates being developed against them,highlighting key epidemiological facts about the diseases and currentlyavailable treatment options, other than ADCs.
§ A list of key opinion leaders (KOLs) within this domain.
§ An insightful competitiveness analysis of biologicaltargets.
§ An analysis of the partnerships that have been establishedin the recent past.
§ An analysis of theinvestments made.
§ A study of the various grants that have been awarded toresearch institutes engaged in projects related to ADCs, between 2011 and 2019(till April).
§ An elaborate discussion on the various strategies that canbe adopted by the drug developers across key commercialization stages, namelyprior to product launch, during / post launch.
§ An analysis of the key promotional strategies that havebeen adopted by the developers of marketed products.
§ An assessment of the various therapeutics that are beingevaluated in combination with ADCs.
§ A review of the evolution of ADC conjugation technologies.
§ An overview of the studies conducted to better analyzenon-clinical data and support first-in-human (FIH) dose selection in ADCs.
§ An elaborate discussion on various factors that form thebasis for the pricing of ADC products.
§ A case study on manufacturing of ADCs, highlighting the keychallenges, and a list of contract service providers that are involved in thisdomain.
§ A case study on companies offering companion diagnostics.
§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)
To sample report – https://www.rootsanalysis.com/reports/270/request-sample.html
§ Type of payload
§ MMAE
§ DM4
§ Camptothecin
§ AM1
§ MMAF
§ Type of linker
§ VC
§ Sulfo-SPDB
§ SMCC
§ VA
§ Hydrazone linker
§ Others
§ Target Indications
§ Breast Cancer
§ Lymphoma
§ Leukemia
§ Urothelial cancer
§ Lung cancer
§ Ovaria cancer
§ Others
§ Target Antigen
§ CD30
§ HER2
§ CD22
§ CD33
§ Others
§ Small Molecule
§ Technology Providers
§ Seattle Genetics
§ ImmunoGen
§ StemCentRx
§ Immunomedics
§ Others
§ Key Geographies
§ North America
§ Europe
§ Asia Pacific
Transcripts of interviews held with thefollowing senior level representatives of stakeholder companies:
§ Alan Burnett (Professor, School of Medicine, CardiffUniversity)
§ Aldo Braca (President and Chief Executive Officer) andGiorgio Salciarini (Technical Business Development Senior Manager, BSPPharmaceuticals)
§ Anthony DeBoer (Director, Business Development, Synaffix)
§ Christian Bailly (Director of CDMO, Pierre Fabre)
§ Christian Rohlff, (Chief Executive Officer and Founder,Oxford BioTherapeutics)
§ Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)
§ John Burt (Chief Executive Officer, Abzena)
§ Jennifer L. Mitcham (Director, SMARTag ADCs andBioconjugates) and Stacy McDonald (Group Product Manager, Catalent PharmaSolutions)
§ Laurent Ducry (Head of Bioconjugates CommercialDevelopment, Lonza)
§ Mark Wright (Site Head, Piramal Healthcare)
§ Sasha Koniev (Chief Executive Officer & Co-Founder,Syndivia)
§ Tatsuya Okuzumi (Associate General Manager, AjinomotoBio-Pharma Services)
§ Toshimitsu Uenaka (Executive Director) and Takashi Owa(Chief Innovation Officer, Eisai)
§ Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)
Keycompanies covered in the report
§ Bristol Myers Squibb
§ AbbVie
§ Astellas Pharma
§ AstraZeneca
§ Daiichi Sankyo
§ Pfizer
§ Roche / Genentech
§ Synthon
§ Bayer HealthCare
§ Biotest Pharmaceuticals
Formore information please click on the following link:
Other Offerings
1. ADCContract Manufacturing Market (3rd Edition), 2018-2030
2. GeneTherapy Market (3rd Edition), 2019 - 2030
3. Global T-Cell(CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
About Roots Analysis
Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
